Product Code: 30916
KEY FINDINGS
The global pharmaceutical continuous manufacturing market is anticipated to register a CAGR of 10.23%, during the studied period of 2021 to 2028. The market growth is facilitated by key drivers, such as, the increasing adoption of pharmaceutical continuous manufacturing systems, the government initiatives for adopting continuous manufacturing systems, the opportunities for development across emerging markets, the rising production of large molecules and biologics, and the increasing healthcare expenditure.
MARKET INSIGHTS
Continuous manufacturing entails an advanced manufacturing approach conducted by employing end-to-end integration of manufacturing subprocesses, along with a substantial level of control strategies.
The growth of the global pharmaceutical continuous manufacturing market is anticipated to be fueled by the opportunities across the untapped and emerging markets, owing to the availability of enhanced pharmaceutical infrastructure, the increased demand for pharmaceutical continuous manufacturing systems, and the growing number of pharmaceutical industries. Moreover, emerging countries' healthcare industry is also augmenting at a considerable rate, given the increased demand for advanced manufacturing systems, as well as notable government investments, in order to improve the healthcare infrastructure.
REGIONAL INSIGHTS
The global pharmaceutical continuous manufacturing market growth is evaluated by studying the Asia Pacific, North America, Europe, and the rest of the Asia Pacific. The Asia Pacific is anticipated to grow with the highest CAGR over the forecast period, owing to factors such as, the augmenting contract research organization (CRO) and contract manufacturing organization (CMO), and growing investments across the region's pharmaceutical and biopharmaceutical industry.
COMPETITIVE INSIGHTS
Although the industry growth of the pharmaceutical continuous manufacturing market is high, the product differentiation is considerably low. Besides, key players are reluctant to divest from their businesses. With a substantial amount of investment involved, the exit barriers are moderately difficult. As a result, the degree of competitive rivalry is projected as moderate to high, over the forecast period.
Some of the key players operating in the market are, Korsch AG, Pfizer Inc, Eli Lilly & Company, Siemens Healthineers, Thermo Fisher Scientific Inc, etc.
Our report offerings include:
- Explore key findings of the overall market
- Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
- Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
- Market Segmentation cater to a thorough assessment of key segments with their market estimations
- Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
- Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
- Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
- Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
- 1.1. STUDY OBJECTIVES
- 1.2. SCOPE OF STUDY
- 1.3. METHODOLOGY
- 1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
- 2.1. MARKET SIZE & ESTIMATES
- 2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
- 3.1. KEY DRIVERS
- 3.1.1. DEVELOPMENT OPPORTUNITIES IN UNTAPPED EMERGING MARKETS
- 3.1.2. INCREASED ADOPTION OF PHARMACEUTICAL CONTINUOUS MANUFACTURING SYSTEMS
- 3.1.3. RISING GOVERNMENT INITIATIVES FOR THE ADOPTION OF CONTINUOUS MANUFACTURING SYSTEMS
- 3.1.4. RISE IN PRODUCTION OF LARGE MOLECULES AND BIOLOGICS
- 3.1.5. INCREASE IN THE HEALTHCARE EXPENDITURE
- 3.2. KEY RESTRAINTS
- 3.2.1. INCREASING CUSTOMER ANTICIPATIONS
- 3.2.2. LACK OF DEMAND FOR CONTINUOUS MANUFACTURING SYSTEMS IN UNDERDEVELOPED COUNTRIES
4. KEY ANALYTICS
- 4.1. PORTER'S FIVE FORCE ANALYSIS
- 4.1.1. THREAT OF NEW ENTRY
- 4.1.2. THREAT OF SUBSTITUTION
- 4.1.3. BUYER'S POWER
- 4.1.4. SUPPLIER'S POWER
- 4.1.5. COMPETITIVE RIVALRY
- 4.2. IMPACT OF COVID-19 ON PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET
- 4.3. REGULATORY FRAMEWORK
- 4.4. OPPORTUNITY MATRIX
- 4.5. VENDOR LANDSCAPE
- 4.6. KEY INVESTMENT INSIGHTS
5. MARKET BY PRODUCT
- 5.1. INTEGRATED CONTINUOUS SYSTEM
- 5.2. SEMI-CONTINUOUS SYSTEM
- 5.3. CONTROL & SOFTWARE
6. MARKET BY APPLICATION
- 6.1. FINAL DRUG PRODUCT MANUFACTURING
- 6.2. API MANUFACTURING
7. MARKET BY END-USER
- 7.1. PHARMACEUTICAL COMPANIES
- 7.2. CONTRACT MANUFACTURING ORGANIZATIONS
- 7.3. OTHER END-USERS
8. GEOGRAPHICAL ANALYSIS
- 8.1. NORTH AMERICA
- 8.1.1. MARKET SIZE & ESTIMATES
- 8.1.2. KEY GROWTH ENABLERS
- 8.1.3. KEY CHALLENGES
- 8.1.4. KEY PLAYERS
- 8.1.5. COUNTRY ANALYSIS
- 8.1.5.1. UNITED STATES
- 8.1.5.2. CANADA
- 8.2. EUROPE
- 8.2.1. MARKET SIZE & ESTIMATES
- 8.2.2. KEY GROWTH ENABLERS
- 8.2.3. KEY CHALLENGES
- 8.2.4. KEY PLAYERS
- 8.2.5. COUNTRY ANALYSIS
- 8.2.5.1. GERMANY
- 8.2.5.2. FRANCE
- 8.2.5.3. UNITED KINGDOM
- 8.2.5.4. ITALY
- 8.2.5.5. RUSSIA
- 8.2.5.6. BELGIUM
- 8.2.5.7. POLAND
- 8.2.5.8. REST OF EUROPE
- 8.3. ASIA PACIFIC
- 8.3.1. MARKET SIZE & ESTIMATES
- 8.3.2. KEY GROWTH ENABLERS
- 8.3.3. KEY CHALLENGES
- 8.3.4. KEY PLAYERS
- 8.3.5. COUNTRY ANALYSIS
- 8.3.5.1. CHINA
- 8.3.5.2. INDIA
- 8.3.5.3. JAPAN
- 8.3.5.4. AUSTRALIA & NEW ZEALAND
- 8.3.5.5. SOUTH KOREA
- 8.3.5.6. THAILAND
- 8.3.5.7. INDONESIA
- 8.3.5.8. VIETNAM
- 8.3.5.9. REST OF ASIA PACIFIC
- 8.4. REST OF WORLD
- 8.4.1. MARKET SIZE & ESTIMATES
- 8.4.2. KEY GROWTH ENABLER
- 8.4.3. KEY CHALLENGE
- 8.4.4. KEY PLAYERS
- 8.4.5. REGIONAL ANALYSIS
- 8.4.5.1. LATIN AMERICA
- 8.4.5.2. MIDDLE EAST & AFRICA
9. COMPETITIVE LANDSCAPE
- 9.1. KEY STRATEGIC DEVELOPMENTS
- 9.1.1. MERGER & ACQUISITIONS
- 9.1.2. PRODUCT LAUNCH & DEVELOPMENTS
- 9.1.3. PARTNERSHIP, CONTRACT/AGREEMENT & COLLABORATION
- 9.1.4. BUSINESS EXPANSION/ APPROVAL/ ANNOUNCEMENT
- 9.2. COMPANY PROFILE
- 9.2.1. COPERION GMBH
- 9.2.2. ELI LILLY & COMPANY
- 9.2.3. GEA GROUP AG
- 9.2.4. GEBRUDER LODIGE MASCHINENBAU GMBH
- 9.2.5. GLATT GMBH
- 9.2.6. HOSOKAWA MICRON CORPORATION
- 9.2.7. KORSCH AG
- 9.2.8. LB BOHLE MASCHINEN + VERFAHREN GMBH
- 9.2.9. MUNSON MACHINERY COMPANY
- 9.2.10. PFIZER INC
- 9.2.11. SIEMENS HEALTHINEERS
- 9.2.12. SYNTEGON (FORMERLY BOSCH PACKAGING TECHNOLOGY)
- 9.2.13. THERMO FISHER SCIENTIFIC INC
比較リスト
